Evidence map›Paper›PMID 42908667›Full record

Observational studyFrontiers in endocrinology2026

Development and external validation of a nomogram for identifying patients with thyroid eye disease who screen positive for depressive symptoms: a two-center study.

Shengzhi Jiao, Liuzi Wang, Jingwen Wang, Wenle Zhang, Jianing Li, Huanhuan Chen, Bei Wang

Abstract readMulticenter StudyObservational StudyValidation Study
In one paragraph

Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shengzhi JiaoNanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Liuzi WangNanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Jingwen WangNanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Wenle ZhangNanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Jianing LiAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Huanhuan ChenDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Bei WangAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To identify factors independently associated with a positive depressive symptom screen in patients with thyroid eye disease (TED) and to develop and externally validate a nomogram-based model for individualized identification in a second-center cohort as a clinically feasible screening tool for prioritizing depressive symptom screening and informing ongoing follow-up and targeted multidisciplinary management. Methods: In this two-center observational study, a development cohort (n=218; October 2025-January 2026) and an external validation cohort (n=88; February-March 2026) were enrolled from two tertiary hospitals in Jiangsu Province (total 306 patients). A positive depressive symptom screen was defined as a PHQ-9 total score ≥5. Independent associated factors were selected by univariate and multivariate logistic regression. Five models were developed using the same development data and preprocessing pipeline: logistic regression, LASSO, support vector machine, random forest, and XGBoost. The entire modeling process was internally validated and corrected for optimism using 500 bootstrap resamples, and hyperparameters were optimized using stratified five-fold cross-validation. Discrimination (AUC), decision curve analysis (DCA), and external validation were assessed, and the final locked model was applied to the external cohort without updating. Results: Overall, 116/306 patients (37.9%) screened positive for depressive symptoms. Age, average monthly household income, stressful life events in the past 6 months, EUGOGO severity grade, standardized GO-QoL-AP score, and TRAb level were independent factors associated with a positive depressive symptom screen. The optimism-corrected AUCs of the five models ranged from 0.736 to 0.790, with no statistically significant paired differences between the corrected AUC of logistic regression and those of the other models. Logistic regression was selected and locked. Its apparent development-cohort AUC was 0.815 and its 500-bootstrap-corrected AUC was 0.776 (95% CI, 0.724-0.840; Brier score, 0.186). In external validation, the AUC was 0.742 (95% CI, 0.631-0.843), the Brier score was 0.195, the calibration slope was 0.981, and the calibration intercept was 0.007. At the locked threshold of 0.312, sensitivity was 0.771 and specificity was 0.547. DCA showed some clinical net benefit across threshold probabilities of 0.10-0.50. Conclusions: We developed a nomogram for identifying patients with TED who screen positive for depressive symptoms based on age, mean monthly household income, stressful life events during the preceding 6 months, EUGOGO severity grade, standardized GO-QoL-AP score, and TRAb level. In second-center external validation, the model showed moderate discrimination, with calibration slope and intercept estimates close to their ideal values. It may serve as an auxiliary tool for prioritizing depressive symptom screening among patients with TED aged 18-59 years.

Indexed as

DepressionGraves OphthalmopathyNomogramsAdultChinaCohort StudiesFemaleHumansMaleMass ScreeningMiddle Ageddepressive symptom screeningexternal validationnomogramprediction modelthyroid eye disease

Identifiers

PMID42908667
PMCPMC13683227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.